Company Profile
Parabon NanoLabs, Inc.
Company Overview
Parabon NanoLabs, Inc. is a vertically integrated DNA technology company that develops next-generation therapeutic and forensic products, which leverage the enormous power of DNA. Staffed by a uniquely qualified team of scientists and technologists, with expertise ranging from bioinformatics and oncology to chemistry and computer science, the Company is bringing to market revolutionary new products and services made possible by recent advances in DNA sequencing, processing and manufacturing technologies.
Company History
In 2005, Dr. Michael Norton, a pioneer in the field of DNA-based nanotechnology, and Dr. Steven Armentrout, serving as CEO of Parabon Computation (PCI), began discussing the computational roadblocks then hindering progress in the field of DNA nanotechnology. Over the next few years, PCI developed the inS?quio™ Design Studio, an innovative software application that enables DNA researchers to design and optimize nanostructures made with DNA self-assembly. On 4 March 2008, after proving the commercial potential of their DNA nanotechnology in the laboratory, PCI and Dr. Norton founded Parabon NanoLabs with the mission to create breakthrough products using DNA. The initial focus was to develop oncology therapeutics using DNA nanostructures. Other therapeutic applications soon followed, such as the development of synthetic vaccines using similar DNA technology. In recent years, the Company applied the bioinformatics infrastructure it developed for drug development to the problem of DNA phenotyping and is now also developing trait prediction capabilities for forensics applications.
Benefits
Flexible spending accounts (medical and dependent), flexible scheduling